Interleukin-6 is an independent predictor of mortality in patients starting dialysis treatment
Interleukin-6 is an independent predictor of mortality in patients starting dialysis treatment
复制标题
DOI：
10.1093/ndt/17.9.1684
复制
发表时间：
2002-09-01
影响因子：
6.1
通讯作者：
Stenvinkel, P
中科院分区：
文献类型：
--
作者：
Pecoits-Filho, R;Bárány, P;Stenvinkel, P
背景终末期肾病（ESRD）患者的死亡率很高，最近的证据表明这可能与炎症有关。白细胞介素-6（IL-6）及其可溶性受体（sIL-6 R）的活性在终末期肾病（ESRD）患者中显著上调，血浆IL-6水平可预测血液透析（HD）患者的预后。然而，尚不确定血浆IL-6升高是否也可预测接受腹膜透析（PD）治疗的ESRD患者的结局，以及其与HD患者数据的关系。sIL-6 R水平对预后的预测能力在该患者人群中也是未知的。为了确定血浆IL-6和sIL-6 R是否能预测患者的生存率，我们研究了173例接近透析治疗开始的ESRD患者（62%男性，53 ± 1岁）（99例PD，74例HD患者）。随访患者平均3.1+/-0.1年（范围0.1-7.1年），并在透析治疗开始时根据年龄、性别、心血管疾病、营养不良（通过主观全面评估确定）、糖尿病、IL-6和sIL-6 R血浆水平进行分层。差异显著（P
Background. The mortality rate is high among end-stage renal disease (ESRD) patients, and recent evidence suggests that this may be linked to inflammation. The activity of interleukin-6 (IL-6) and its soluble receptor (sIL-6R) are markedly up-regulated in ESRD patients, and plasma IL-6 levels predict outcome in haemodialysis (HD) patients. However, it has not been established whether elevated plasma IL-6 also predicts outcome in ESRD patients treated by peritoneal dialysis (PD), and how it relates to the data on HD patients. The predictive power of sIL-6R levels on outcome is also unknown in this patient population.Methods. To determine whether or not plasma IL-6 and sIL-6R predict patient survival, we studied 173 ESRD patients (62% males, 53+/-1 years of age) near the initiation of dialysis treatment (99 PD, 74 HD patients). The patients were followed for a mean period of 3.1+/-0.1 years (range 0.1-7.1 years) and were stratified at the start of dialysis treatment according to age, gender, presence of cardiovascular disease, malnutrition (determined by subjective global assessment), diabetes mellitus, and IL-6 and sIL-6R plasma levels.Results. A significantly different (P